trending Market Intelligence /marketintelligence/en/news-insights/trending/Y-dUj405L25BOcCnkScgfw2 content esgSubNav
In This List

OrthoPediatrics' foot deformity system for children wins US FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


OrthoPediatrics' foot deformity system for children wins US FDA approval

OrthoPediatrics Corp. said its PediFoot Deformity Correction System became the first system specifically for children to treat fractures and deformities of the foot and ankle to be approved by the U.S. Food and Drug Administration.

The Warsaw, Ind.-based medical device company said in an Aug. 19 press release that the PediFoot system is intended for fixing fractures, osteotomies — surgical cutting of a bone — nonunions, replantations, and fusions of small bones and small bone fragments.

The system addresses certain deformities in children, including cavus foot, flatfoot, clubfoot, and hallux valgus — a condition in which the foot has a very high arch.

OrthoPediatrics' Vice President Joe Hauser said the company will launch the system in the third quarter.